Raptor makes $40M offering to advance PhIII rare disease treatments
This article was originally published in Scrip
Executive Summary
In a proposed offering, Raptor Pharmaceutical, which focuses on treatments for rare disorders, has priced 10 million shares of it common stock at $4, a modest discount to its 7 September closing share price of $4.35.